Low Dose of Hydrocortisone and Fludrocortisone in Adult Cardiogenic Shock. (COCCA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03773822|
Recruitment Status : Recruiting
First Posted : December 12, 2018
Last Update Posted : October 17, 2019
|Condition or disease||Intervention/treatment||Phase|
|Cardiogenic Shock||Combination Product: Hydrocortisone + Flucortac Other: Placebo||Phase 3|
Cardiogenic shock is a serious condition with a high mortality rate, characterized by acute dysfunction of the heart pump. Critical illness-related corticosteroid insufficiency is a pathophysiological concept, first described in septic shock. It is characterized by an impairment of the hypothalamic pituitary axis during critical illness. Its diagnosis is usually suggested by an inappropriate response to the adrenal stimulation test. The results of corticosteroid supplementation studies in septic shock are controversial, but most of these studies demonstrate that corticosteroid therapy improves reversal of shock.
The concept of critical illness-related corticosteroid insufficiency has recently been expanded to cardiogenic shock. The latter has many physiopathological similarities with septic shock. However, no studies have evaluated the effect of supplemental corticosteroid supplementation in cardiogenic shock.
The purpose of this study is to evaluate the hemodynamic effect of low dose corticosteroid therapy in the treatment of adult cardiogenic shock.
This study is a multicenter, randomized, double blinded, placebo controlled trial comparing intravenous hydrocortisone (50 mg intravenously every 6 hours) plus enteral fludrocortisone (50 µg/day) with placebo for seven days in critically ill patients with cardiogenic shock.
The primary endpoint for this trial will be catecholamine-fee days at day-7. Secondary endpoints will include all-cause mortality at 28 and 90 days after randomisation.
Several pre-defined sub-groups analyses are planned, including: postcardiotomy, myocardial infarction, etomidate use, vasopressor use...
380 patients will be enrolled in this study at approximately 20 study sites. Each patient will be followed-up for 90 days.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||380 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Low Dose of Hydrocortisone and Fludrocortisone in Adult Cardiogenic Shock. A Multicenter, Prospective, Double-blind, Randomized, Placebo-controlled Study|
|Actual Study Start Date :||April 19, 2019|
|Estimated Primary Completion Date :||April 20, 2021|
|Estimated Study Completion Date :||July 20, 2021|
Placebo Comparator: Placebo of hydrocortisone and placebo of fludrocortisone
Placebo of hydrocortisone as an iv bolus every 6 hours for seven days plus placebo of enteral fludrocortisone given once a day for seven days
Experimental: Combination of hydrocortisone + fludrocortisone
Hydrocortisone will be given as 50 mg iv bolus every 6 hours for seven days and a tablet of 50 µg of fludrocortisone will be given once a day enterally for seven days
Combination Product: Hydrocortisone + Flucortac
Low dose steroids
- Patients not treated with corticosteroids at day 7 [ Time Frame: 7 days ]
- Mortality at 28 and 90 days after randomisation [ Time Frame: 28 and 90 days after randomisation ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03773822
|Contact: Armand MEKONTSO DESSAP, MD||(+33)1 46 25 24 email@example.com|
|Contact: François BAGATE,, MD||(+33)1 49 81 23 firstname.lastname@example.org|
|Hôpital Henri Mondor||Recruiting|
|Paris, Ile De France, France|
|Contact: Armand MEKONTSO DESSAP, MD|
|Principal Investigator: Armand MEKONTSO DESSAP, MD|
|Sub-Investigator: François BAGATE, MD|
|CMC Ambroise Paré||Recruiting|
|Neuilly sur seine, France, 92200|
|Contact: Pierre SQUARA, MD 0146415079 email@example.com|
|Contact: Messaouda MERZOUG, PhD firstname.lastname@example.org|
|Principal Investigator: Pierre SQUARA, MD|
|Sub-Investigator: Philippe ESTAGNASIE, MD|
|Sub-Investigator: Alain BRUSSET, MD|
|Sub-Investigator: Driss LAGHLEM, MD|